Clinical trials: Viral Respiratory Tract Infections
Post COVID-19 Syndrome, Rehabilitation
Implementation of Rehabilitation Program for Post COVID-19
Many people who have suffered from the effects of this disease might now be at risk of long-term impairment and disability. The extent of this impairment and disability is yet unknown, but it is clear from early research that…
- Trial name
- NCT04694768
- Testing
- Rehabilitation
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
COVID-19, Hypoxemia
iNOPulse for COVID-19
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
- Conditions
- COVID-19, Hypoxemia, Hypoxemic Respiratory Failure
- Trial name
- NO-COVER (NCT04398290)
- Testing
- Inhaled nitric oxide (iNO), Nitrogen gas, Oxygen gas
- Where
- United States
- Sponsor
- Roger Alvarez
COVID-19, SARS-CoV-2
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
Lymphopenia is common in patients with COVID-19 and is associated with worse clinical outcomes. NT-I7 is a long-acting human interleukin-7 (IL-7) that has been shown to increase absolute lymphocyte count (ALC) and CD4+ and CD8+ T…
- Trial name
- NCT04498325
- Testing
- NT-I7, Blood for research purposes, Blood for pharmacokinetic samples
- Sponsor
- Washington University School of Medicine
COVID-19
Assessment of the Response to the Complete Vaccination Guidelines Against Sars-cov2
Prospective observational single-center study in which the impact of anti-TNF biological treatment on the humoral response after complete vaccination against SARS-COV2 in patients with inflammatory bowel disease is analyzed.
- Trial name
- COVID-19 (NCT05153850)
- Where
- Spain
- Volunteers
- 243 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
COVID-19 (Healthy Volunteers)
Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
This is randomized, placebo-controlled, observer-blinded, multi-center study to assess safety, reactogenicity and immunogenicity of booster vaccination of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted…
- Trial name
- NCT05175950
- Testing
- SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, Normal saline
- Where
- 9 sites in South Korea
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
COVID, Vitamin D Deficiency
Vitamin D Levels in SARS-CoV-2: Do Current Adequacy Thresholds Reflect Clinical Risk? Insights From a Large Turkish Cohort
Blood vitamin D levels may be associated with severity of viral infections. To find out If there is a statistically significant relation between blood 25-hydroxy vitamin D (25(OH)D) levels and disease severity, patients with…
- Trial name
- NCT04394390
- Testing
- vitamin d
- Where
- Turkey (Türkiye)
- Volunteers
- 1,100 people
- Sponsor
- Bursa City Hospital
Covid19
Evaluation of a COVID-19 Rapid Diagnostic Test in ER Departments in Mexico: a Multi-center Study
An observational (cross-sectional) study in the emergency services of participating hospitals, receiving patients with COVID-19 and influenza, aiming to evaluate the diagnostic performance of the rapid antigen detection test for…
- Trial name
- NCT04894760
- Testing
- Rapid Antigen Test (PanBio Ag test)
- Where
- Mexico
- Volunteers
- 567 people
- Sponsor
- National Institute of Respiratory Diseases, Mexico
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management…
- Conditions
- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
- Trial name
- PREVAIL (NCT05472090)
- Testing
- TNX-102 SL
- Where
- 29 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
COVID-19
Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
The Covid-19 has, in a few weeks, made the world tremble: the number of deaths (mainly elderly and / or co-morbid) continues to increase, the confinement causes the collapsing of the economy and the decline of relationships…
- Trial name
- PAPESCO-19 (NCT04421625)
- Testing
- Diagnostic test for SARS-Cov2 for patients and health staff
- Where
- 3 sites in France
- Volunteers
- 1,102 people, healthy volunteers welcome
- Sponsor
- Institut Cancerologie de l'Ouest
COVID-19, Myocardial Injury
Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19
COVID-19 outbreak is often lethal. Mortality has been associated with several cardio-vascular risk factors such as diabetes, obesity, hypertension and tobacco use.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis
- Trial name
- JOCOVID (NCT04320017)
- Testing
- Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
SARS-CoV2
Clinical Features of Severe Patients With COVID-19
As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive care unit (ICU) community must prepare for the challenges associated with this pandemic.
- Trial name
- NCT04450017
- Testing
- The demographic, clinical, laboratory, and instrumental data
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2, BCG
SARS-CoV-2/COVID-19 Infection Among Health Care Workers
The present study finds opportunities and justifications, taking into consideration that the nature of professional practice in health needs scientific evidence resulting from systematic and systemic studies to strengthen the…
- Conditions
- SARS-CoV-2, BCG, Health Care Worker, COVID-19
- Trial name
- NCT04826718
- Testing
- Questionaire
- Where
- Cabo Verde
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Universidade de Cabo Verde
Gastric Cancer, COVID-19 Pandemic
The Impact of COVID-19 Pandemic on Clinical Presentation and Staging of Gastric Cancer
This was a retrospective case-control study designed and conducted under the approval of the ethic committee of Tehran University of Medical Sciences.
- Conditions
- Gastric Cancer, COVID-19 Pandemic, Peritoneal Metastases
- Trial name
- NCT05130710
- Testing
- staging laparoscopy
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Tehran University of Medical Sciences
COVID-19
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of STI-1558 in adult subjects with mild/moderate COVID-19.
- Trial name
- NCT05716425
- Testing
- STI-1558
- Where
- 2 sites in China
- Volunteers
- 1,218 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
Covid19
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
This study will assess the safety, tolerability and immunogenicity of DS-5670a (COVID-19 Vaccine) and determine the recommended dose in Japanese healthy adults and elderly participants.
- Trial name
- NCT04821674
- Testing
- DS-5670a
- Where
- Japan
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
COVID-19
Impact of the CT Scan in Patients With Suspected Covid-19
The diagnostic performance of the scanner in the indication of suspected Covid-19 is not yet well known, especially in comparison with the results of RT-PCR.
- Trial name
- SCAN-COV-HUS (NCT05079191)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Efficacy of Nicotine in Preventing COVID-19 Infection
The coronavirus disease (COVID-19) epidemic represents a major therapeutic challenge. The highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) and the long duration of the disease have led to a massive…
- Trial name
- NICOVID-PREV (NCT04583410)
- Testing
- Nicotine patch
- Where
- 4 sites in France
- Volunteers
- 1,633 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.